Using a Gastric Bypass Stent to Treat Liver Fibrosis in Obese Patients

A Prospective, Open-label, Single-arm Clinical Study to Evaluate the Safety and Performance of the Gastric Bypass Stent System as a Treatment for Hepatic Fibrosis in Obese Patients in European Region

This study is testing a new stent treatment for liver fibrosis in obese patients to see if it helps improve their liver health and aids in weight loss.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 10 (estimated)
• Ages: 18 Years to 65 Years
• Sex: All
• Sponsor: Mdcecro LLC (Research network)
• Locations: 2 sites (Riga, Riga and 1 other locations)
• Trial ID: NCT06561529 on ClinicalTrials.gov

What this trial studies

This clinical investigation evaluates the safety and performance of the Gastric Bypass Stent System as a non-invasive treatment for hepatic fibrosis in obese patients. It is a pilot, prospective, single-arm study conducted in Europe, focusing on individuals with suspected or confirmed NASH fibrosis. Participants will undergo treatment with the stent system to assess its effectiveness in managing liver fibrosis while also promoting weight loss.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18-65 with a BMI of 30 kg/m² or higher and confirmed NASH liver fibrosis.

Not a fit: Patients with liver fibrosis stages outside of 1-3 or those who do not meet the specific eligibility criteria may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could provide a new non-invasive treatment option for obese patients suffering from liver fibrosis.

How similar studies have performed: While the use of gastric bypass techniques for weight loss is well-established, the application of the Gastric Bypass Stent System for treating liver fibrosis is a novel approach that has not been extensively tested in previous studies.

Eligibility criteria

Subjects who meet all of the following criteria are eligible for this clinical investigation:

1. Age 18-65 years.
2. BMI ≥ 30 kg/m².
3. Medical history suggests suspected or confirmed NASH fibrosis. Meeting any of the following criteria indicates NASH liver fibrosis:

   * Historical biochemical tests for fibrosis: PRO-C3 \>14 ng/mL or ELF ≥9
   * Fibroscan, transient elastography ≥8.5 kPa, controlled attenuation parameter ≥280 dB/m
   * Based on existing pathology review, liver biopsy within \<2 years before the expected randomization shows stage 1B, 2, or 3 fibrosis NASH, with no significant weight change \>5% or medications likely affecting NAS or fibrosis stage.
4. Liver biopsy confirming NASH within 6 months before the randomization date, with liver biopsy fibrosis stage 1-3, NAS ≥3, and at least a score of 1 for the following NAS components:

   * Steatosis (0-3 points)
   * Ballooning (0-2 points)
   * Lobular inflammation (0-3 points)
5. Patients who have not achieved effective results after three months of lifestyle modifications and non-invasive treatments (non-diabetic patients have not achieved a weight loss of 5%, diabetic patients have not achieved a weight loss of 3%).
6. Able and willing to provide informed consent for participation in the clinical investigation and comply with all study procedures and assessments.

Subjects who meet any of the following criteria are not eligible for this clinical investigation:

1. Patients with liver cirrhosis
2. Patients with secondary obesity; a medical condition that has caused weight gain such as endocrine disorders and hypothalamic disorders.
3. Chronic, daily use of systemic anti-inflammatory or corticosteroid medications (e.g., ibuprofen, prednisolone) for more than 1 week (not including low-dose aspirin for cardiac prophylaxis or inhaled corticosteroids).
4. Patients with less than one-year continuous treatment before baseline with hypoglycemic drugs with known weight loss effects (e.g., GLP-1 agonists, SGLT-2 inhibitors, DDP-4 inhibitors).
5. Patients diagnosed with type 1 diabetes.
6. Patients with the function of islet β cell basically lost, C-peptide ≤ 1/2 of the normal low limit, or low and flat C-peptide release curve under glucose load.
7. Patients with significant iron deficiency or iron deficiency anemia upon the Investigator's discretion.
8. Patients with coagulation dysfunction and chronic, daily use of systemic anti-inflammatory or anti-coagulation medication in the past month (not including low-dose aspirin).
9. Patients with severe liver and kidney dysfunction, and a serum creatinine concentration ≥ 180 μmol/L.
10. Patients with Class III heart function of New York Heart Association Functional Classification (NYHA) or higher upon the Investigators evaluation.
11. Patients who have undergone Endoscopic Retrograde Cholangiopancreatography (ERCP) or have a history of cholecystitis or liver abscess, as assessed by medical history and abdominal ultrasound.
12. Patients with a duodenal ulcer, gastric ulcer, or previous and existing pancreatitis, as assessed by abdominal ultrasound, gastroscopy (prior to the procedure at Visit 3), and medical history.
13. Patients with gallstones (diameter ≥ 20 mm) with clinical symptoms as assessed by abdominal ultrasound and medical history.
14. Patients with on-going thyroid dysfunction, not stabilized despite appropriate treatment.
15. Patients with hemorrhage or potential hemorrhage in the digestive tract.
16. Patients with gastrointestinal tract anomalies, such as gastrointestinal tract atresia, or other conditions that would result in failed placement in the gastrointestinal tract, as assessed by gastroscopy (prior to the procedure at Visit 3), abdominal digital gastrointestinal radiography, and medical history.
17. Patients with a history of bowel obstruction or related diseases in the past year.
18. Patients with a history of systemic lupus erythematosus or scleroderma.
19. Patients with severe infections that are not controlled.
20. Patients with poor general condition and having endoscopic contraindications (as evaluated by the Investigator).
21. Pregnant women or planning to become pregnant.
22. Patients with an alcohol dependence or substance abuse.
23. Patients with unstable psychiatric disorders.
24. Patients who are enrolled in another investigational study and have not completed the required follow-up period.
25. Patients with an allergy to any of the components of the investigational device.
26. Patients with any other conditions evaluated by the Investigators as unsuitable for participating in the clinical investigation.
27. Patients who are positive for hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus as determined by antibodies, deoxy/ribonucleic acid (DNA/RNA), or antigens.

Note: Anti-HCV positive, but HCV-RNA negative HCV patients can be included, based on investigator's judgement, if it's not the primary reason for the fibrosis. Anti-HBc positive, but HBs-Ag negative patients can be included, based on investigator's judgement.

Where this trial is running

Riga, Riga and 1 other locations

• REUH, hospital "lnfectology center of Latvia" — Riga, Riga, Latvia (Recruiting)
• Digestive Diseases Centre "GASTRO" — Riga, Latvia (Recruiting)

Study contacts

• Study coordinator: Mdce Cro

Conditions Fibrosis; Liver